SEC Form 4 · accession 0001209191-18-049134
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Aselage
Officer — Chief Executive Officer · Director
Period of report
Aug 31, 2018
Accepted (ET)
Aug 31, 2018 · 7:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2018 | M | 12,000 | $8.70 | A | 257,883 | D | |
| Common Stock | Aug 31, 2018 | S | 12,000 | $32.00 | D | 245,883 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy) | $8.70 | Aug 31, 2018 | M | 12,000 | D | Dec 6, 2013 | Dec 6, 2023 | Common Stock | 12,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.